Irinotecan liposomes combined with cisplatin/carboplatin
ApprovedSmall molecule
Irinotecan liposomes combined with cisplatin/carboplatin is one of 43 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
96 competitors in Neuroendocrine Carcinoma
#DrugCompanyPhaseTrials
1Tarlatamab-Dznl
AmgenPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Sandostatin LAR
NovartisPhase 3
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Afinitor
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroendocrine Carcinoma1 trial
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT06485739·20 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details